Inventiva soars on positive trial data for lanifibranor

Inventiva SA

14/06/2023 09:13

** Shares in Inventiva  IVAA.PA  surge more than 20% after
the French biotechnology company announced positive phase 2 data
for its lanifibranor drug in fatty liver disease
    ** This data boosts investor sentiment and is derisking
phase 3 of the development, Jefferies says
    ** "Encouragingly, these findings are consistent with Phase
IIb NATIVE data in non-alcoholic steatohepatitis (NASH), in
which lanifibranor demonstrated a statistically significant
steatosis reduction by CAP/Fibroscan, and also histological
improvements by biopsy," the broker adds
    ** Jefferies notes the broad cardiometabolic benefits to the
drug may be viewed favourably by payers and "should translate
into improved liver and cardiovascular related outcomes
necessary for full approval by regulators"
    ** That said, the broker is still waiting for more
incremental details on safety
    ** The stock is set for best day since October 2022

 (Reporting by Gaëlle Sheehan)
 ((gaelle.sheehan@thomsonreuters.com; +48 58 7785110))